Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma

Table 1 Clinicopathological characteristics of patients with surgically treated ampulla of Vater carcinoma according to the adjuvant treatment, n (%)

Variables	Total (n = 104)	AC (n = 52)	Surgery alone (n = 52)	P value
Age, median (range)	64 (49-83)	69 (62-83)	64 (49-83)	0.924
Gender
Male	58 (55.8)	33 (56.9)	25 (43.1)	0.114
Female	46 (44.2)	19 (41.3)	27 (58.7)
Tumor size (cm), mean ± SD	2.5 ± 1.1	2.6 ± 1.3	2.4 ± 1.0	0.314
Resection status
R0	102 (98.0)	50 (49.0)	52 (51.0)	0.495
R1	2 (2.0)	2 (100)	0
Histologic grading
Grade 1/2	94 (90.3)	45 (47.9)	49 (52.1)	0.319
Grade 3	10 (9.7)	7 (70.0)	3 (30.0)
Tumor stage
T1-2	56 (53.8)	23 (41.1)	33 (58.9)	0.049
T3-4	48 (46.2)	29 (60.4)	19 (39.6)
Node stage
N0	45 (43.3)	14 (31.1)	31 (68.9)	0.001
N1-2	59 (56.7)	38 (64.4)	21 (35.6)
TNM stage1
Stage IB	30 (28.8)	8 (26.7)	22 (73.3)	0.002
Stage II	15 (14.4)	6 (40.0)	9 (60.0)
Stage III	59 (56.8)	38 (64.4)	21 (35.6)
Lymphatic invasion
No	42 (40.4)	13 (31.0)	29 (69.0)	0.001
Yes	62 (59.6)	39 (62.9)	23 (37.1)
Vascular invasion
No	81 (77.9)	34 (42.0)	47 (58.0)	0.002
Yes	23 (22.1)	18 (78.3)	5 (21.7)
Perineural invasion
No	74 (71.2)	32 (43.2)	42 (56.8)	0.030
Yes	30 (28.8)	20 (66.7)	10 (33.3)
Preoperative CA19-9 level
Within normal (< 40 U/mL)	45 (43.3)	22 (48.9)	23 (51.1)	0.516
Above normal (≥ 40 U/mL)	43 (41.3)	24 (55.8)	19 (44.2)
Missig data	16 (15.4)

¹According to American Joint Committee on Cancer 8^th edition. AC: Adjuvant chemotherapy; TNM: Tumor, node, metastasis; CA 19-9: Carbohydrate antigen 19-9.